Er:YAG AFL-PDT

Phase 1Small molecule

DDong-A University

Er:YAG AFL-PDT is one of 6 small molecule programs targeting Cheilitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CheilitisActive, not recruiting

CheilitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Cheilitis

#DrugCompanyPhaseTrials

Aldara

BBausch Health Americas, Inc.

Approved

—2

Aminolevulinic Acid Hydrochloride

MMayo Clinic

Approved

1 3

Ingenol Metabute

LEO Pharma

Phase 2

1 4

Dexpanthenol

Bayer

Phase 1

1 5

Er:YAG AFL-PDT

DDong-A University

Phase 1

1 6

MAL-PDT

DDong-A University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cheilitis1 trial

Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis

Completed·—·Phase 1·NCT02198469·33 enrolled

Unspecified1 trial

Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease

Completed·—·Phase 1·NCT01912976·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Er:YAG AFL-PDT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Er:YAG AFL-PDT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Er:YAG AFL-PDT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dong-A University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDong-A University

Er:YAG AFL-PDT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cheilitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News